[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638560":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":38,"centralContacts":43,"locations":49,"responsibleParty":90,"collaborators":26,"id":92,"slug":93,"hasResults":94,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":26,"eligibilityCriteria":97,"healthyVolunteers":94,"sex":98,"minAge":99,"maxAge":26,"enrollmentInfo":100,"targetDuration":26,"studyType":103,"phases":104,"briefSummary":106,"conditions":107,"keywords":26,"overallStatus":110,"whyStopped":26,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},{"fullName":5,"class":6},"Alcon Research","INDUSTRY",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"LPYWT0 \u002F PXYWT0","OTHER","Investigational IOL Model LPYWT0 implanted in the first operative eye during cataract surgery with Clareon PanOptix Pro IOL Model PXYWT0 in the second eye, as randomized. The second eye will be implanted 7-14 days after the first.",[13,14,15],"Device: LPYWT0","Device: PXYWT0","Procedure: Cataract Surgery",{"label":17,"type":10,"description":18,"interventionNames":19},"PXYWT0 \u002F LPYWT0","Clareon PanOptix Pro IOL Model PXYWT0 implanted in the first operative eye during cataract surgery with investigational IOL Model LPYWT0 implanted in the second eye, as randomized. The second eye will be implanted 7-14 days after the first.",[13,14,15],[21,27,33],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","LPYWT0","Investigational blue light filtering trifocal IOL implanted in the capsular bag of the eye during cataract surgery intended to remain in the eye for the lifetime of the subject.",[9,17],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"PXYWT0","Commercially available blue light filtering trifocal IOL implanted in the capsular bag of the eye during cataract surgery intended to remain in the eye for the lifetime of the subject.",[9,17],[32],"Clareon® PanOptix® Pro",{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":26},"PROCEDURE","Cataract Surgery","Removal of the cataractous lens by phacoemulsification followed by implantation of the IOL",[9,17],[39],{"name":40,"affiliation":41,"role":42},"Clinical Trial Lead, Surgical","Alcon Research, LLC","STUDY_DIRECTOR",[44],{"name":45,"role":46,"phone":47,"phoneExt":26,"email":48},"Alcon Call Center","CONTACT","1-888-451-3937","alcon.medinf@alcon.com",[50,63,72,84],{"facility":51,"status":26,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":26},"Dr. Agarwal's Eye Hospital Limited","Chennai","Tamil Nadu","600018","India","IN",{"type":58,"coordinates":59},"Point",[60,61],80.27847,13.08784,{"lat":61,"lon":60},{"facility":64,"status":26,"city":65,"state":26,"zip":66,"country":55,"countryCode":56,"cosmosGeoPoint":67,"geoPoint":71,"contacts":26},"Narayana Nethralaya","Bangalore","560010",{"type":58,"coordinates":68},[69,70],77.59369,12.97194,{"lat":70,"lon":69},{"facility":73,"status":26,"city":74,"state":75,"zip":76,"country":77,"countryCode":78,"cosmosGeoPoint":79,"geoPoint":83,"contacts":26},"Peregrine Eye Laser and Institute","Makati City","Manila","1209","Philippines","PH",{"type":58,"coordinates":80},[81,82],121.03269,14.55027,{"lat":82,"lon":81},{"facility":85,"status":26,"city":74,"state":26,"zip":86,"country":77,"countryCode":78,"cosmosGeoPoint":87,"geoPoint":89,"contacts":26},"Asian Eye Institute","1200",{"type":58,"coordinates":88},[81,82],{"lat":82,"lon":81},{"type":91,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100638560","clinical-evaluation-of-a-novel-trifocal-iol-100638560",false,"NCT07587138","Clinical Evaluation of a Novel Trifocal IOL","Key Inclusion Criteria:\n\n* The calculated power needed for the artificial lens (IOL) must be between +15.0 and +25.0 D in each eye, designed to bring subject vision as close to \"0.0\" (neutral) as possible, meaning they will not be strongly nearsighted or farsighted after surgery.\n* Subjects must have low levels of astigmatism (misshapen cornea) in the eyes (less than 1.00 D).\n* In the doctor's opinion, the subjects have the potential to achieve good vision (0.2 logMAR, which is roughly 20\u002F32 Snellen or better) in each eye after the surgery, when wearing the best possible spectacles or contact lenses.\n* Other protocol-specified inclusion criteria may apply.\n\nKey Exclusion Criteria:\n\n* Clinically significant corneal diseases which may, according to the investigator's medical opinion, adversely affect visual outcomes.\n* Any ocular or systemic health condition or medical issue that, in the investigator's medical opinion, could make the study results unreliable, prevent the person from finishing the study, or increase their safety risk.\n* People who want to have one eye set for distance vision and the other for near vision.\n* The doctor expects significant blurry vision (astigmatism) after the procedure.\n* Other protocol-specified exclusion criteria may apply.","ALL","22 Years",{"count":101,"type":102},66,"ESTIMATED","INTERVENTIONAL",[105],"NA","The purpose of this study is to understand the visual outcomes of the investigational intraocular lens (IOL) Model LPYWT0 when compared to the commercially marketed Clareon PanOptix Pro IOL Model PXYWT0.",[108,109],"Aphakia","Cataract","NOT_YET_RECRUITING","2026-05-14",{"date":113,"type":114},"2026-05-18","ACTUAL",{"date":116,"type":102},"2026-10",{"date":118,"type":102},"2027-07",{"name":5,"class":6},4]